VEGF (Vascular endothelial growth factor, VEGFA, VEGF-A), a dimeric ligand, is among the most potent angiogenic mitogens. VEGF is secreted by tumor cells and other cells exposed to hypoxia. VEGF is a highly specific mitogen for vascular endothelial cells. Seven VEGF isoforms (a, b, c, d, e, f, g) are generated as a result of alternative splicing from a single VEGF gene. All seven isoforms differ in their molecular mass and in biological properties such as their ability to bind to cell-surface heparan-sulfate proteoglycans. The expression of VEGF is potentiated and is secreted by tumor cells in response to hypoxia, by activated oncogenes, and by a variety of cytokines.
Product Information
Format
Affinity Purified
Control
Jurkat cell lysate
Presentation
Liquid in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6 containing 0.1% sodium azide.
Applications
Application
Anti-VEGF Antibody, clone CH-10 is an antibody against VEGF for use in WB.
Key Applications
Western Blotting
Biological Information
Immunogen
Recombinant mouse VEGF.
Clone
CH-10
Concentration
Please refer to the Certificate of Analysis for the lot-specific concentration.
Host
Mouse
Specificity
This antibody recognizes human and rat VEGF, other variants not tested.
This gene product is a member of the PDGF/VEGF growth factor family. It is a mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. Also, alternative translation initiation from non-AUG (CUG) and AUG start sites in some transcript variants, give rise to additional isoforms.
FUNCTION:Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis, and induces permeabilization of blood vessels. Binds to the VEGFR1/Flt-1 and VEGFR2/Kdr receptors, heparan sulfate and heparin. Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to VEGFR2/Kdr but doesn't activate downstream signaling pathways, doesn't activate angiogenesis and inhibits tumor growth. SUBUNIT STRUCTURE:Homodimer; disulfide-linked. Also found as heterodimer with PlGF By similarity. SUBCELLULAR LOCATION:Secreted. Note: VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. TISSUE SPECIFICITY:The VEGF189, VEGF-165 and VEGF-121 isoforms are widely expressed, whereas the VEGF206 and VEGF-145 are uncommon. INDUCTION:Regulated by growth factors, cytokines, gonadotropins, nitric oxide, hypoxia, hypoglycemia and oncogenic mutations. SEQUENCE SIMILARITIES:Belongs to the PDGF/VEGF growth factor family. SEQUENCE CAUTION:The sequence CAC19512.2 differs from that shown. Reason: Erroneous gene model prediction.
Product Usage Statements
Quality Assurance
Evaluated by Western Blot in Jurkat cell lysate.
Western Blot Analysis: 1:1000 dilution of this antibody detected VEGF on 10 µg of Jurkat cell lysate.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
VEGF (Vascular endothelial growth factor, VEGFA, VEGF-A), a dimeric ligand, is among the most potent angiogenic mitogens. VEGF is secreted by tumor cells and other cells exposed to hypoxia. VEGF is a highly specific mitogen for vascular endothelial cells. Seven VEGF isoforms (a, b, c, d, e, f, g) are generated as a result of alternative splicing from a single VEGF gene. All seven isoforms differ in their molecular mass and in biological properties such as their ability to bind to cell-surface heparan-sulfate proteoglycans. The expression of VEGF is potentiated and is secreted by tumor cells in response to hypoxia, by activated oncogenes, and by a variety of cytokines.
Product Information
Format
Affinity Purified
Control
Jurkat cell lysate
Presentation
Liquid in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6 containing 0.1% sodium azide.
Applications
Application
Anti-VEGF Antibody, clone CH-10 is an antibody against VEGF for use in WB.
Key Applications
Western Blotting
Biological Information
Immunogen
Recombinant mouse VEGF.
Clone
CH-10
Concentration
Please refer to the Certificate of Analysis for the lot-specific concentration.
Host
Mouse
Specificity
This antibody recognizes human and rat VEGF, other variants not tested.
This gene product is a member of the PDGF/VEGF growth factor family. It is a mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. Also, alternative translation initiation from non-AUG (CUG) and AUG start sites in some transcript variants, give rise to additional isoforms.
FUNCTION:Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis, and induces permeabilization of blood vessels. Binds to the VEGFR1/Flt-1 and VEGFR2/Kdr receptors, heparan sulfate and heparin. Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to VEGFR2/Kdr but doesn't activate downstream signaling pathways, doesn't activate angiogenesis and inhibits tumor growth. SUBUNIT STRUCTURE:Homodimer; disulfide-linked. Also found as heterodimer with PlGF By similarity. SUBCELLULAR LOCATION:Secreted. Note: VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. TISSUE SPECIFICITY:The VEGF189, VEGF-165 and VEGF-121 isoforms are widely expressed, whereas the VEGF206 and VEGF-145 are uncommon. INDUCTION:Regulated by growth factors, cytokines, gonadotropins, nitric oxide, hypoxia, hypoglycemia and oncogenic mutations. SEQUENCE SIMILARITIES:Belongs to the PDGF/VEGF growth factor family. SEQUENCE CAUTION:The sequence CAC19512.2 differs from that shown. Reason: Erroneous gene model prediction.
Product Usage Statements
Quality Assurance
Evaluated by Western Blot in Jurkat cell lysate.
Western Blot Analysis: 1:1000 dilution of this antibody detected VEGF on 10 µg of Jurkat cell lysate.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
